H.C. Wainwright’s Ram Selvaraju commends new CEO Troy Hamilton’s strong background in the biotech-verse and roots for Trulance as a long-term winner in the competitive IBS-C playing field.
Canaccord’s Mark Massaro is impressed that even after recent HTGM share volatility, the healthcare player still delivered an impressive robust fourth quarter turnout for 2017.
Roth Capital’s Yasmeen Rahimi is left bewildered, having banked on the success of OHRP’s wet-AMD asset, but holds out hope to become more positive on the stock down the line.
OMER shares may be seeing a pullback today, but this bull believes the drug maker has a standout product profile in its kidney asset that can save patient lives.
Though in the next 12 months, Cantor’s Louise Chen is hesitant to take a gamble on an Israeli biotech giant just at the beginning of a comeback, she likes what she sees in new TEVA CEO Kare Schultz’s strategy.
Cantor’s William Tanner explains that while TXMD asset TX-004 has magnetized the Street’s attention in the last half a year, TX-004 boasts a bigger commercial market.
Cantor’s Mara Goldstein is not shaken by the $411 million pretax charge impacting CELG in 4Q, as the stock barely dipped past 1% upon the GED-0301 program cancellation news.